SCHEMBL5232143

SCHEMBL5232143

CCCCOc1c(CNC(=O)OC(C)(C)C)n(CC(C)(C)C)c(=O)c2ccc(C(=O)O)cc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CYP1A1 P04798 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2B6 P20813 1/20 0.36
CYP2C19 P33261 1/20 0.36
CYP3A43 Q9HB55 1/20 0.36
TP53 P04637 1/20 0.35
TSHR P16473 1/20 0.35
BRD4 O60885 1/20 0.35
PLA2G4B P0C869 1/20 0.35
DPP4 P27487 2/20 0.35
MAPK8 P45983 1/20 0.34
RARB P10826 3/20 0.34
NR1H4 Q96RI1 2/20 0.34
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5234879 0.92 KDM4E (0.38) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL5231264 0.90 DPP4 (0.46) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL5233075 0.88 ACACB (0.36) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL5233633 0.86 MAPK8 (0.36) ALDH1A1CYP1A1CYP2D6CYP2B6CYP2C19
SCHEMBL5236103 0.85 CYP1A1 (0.36) KDM4EGAACYP1A1CYP2D6CYP2B6
SCHEMBL5237080 0.85 SDCBP (0.35) CYP1A1CYP2D6CYP2B6CYP2C19CYP3A43
SCHEMBL5236095 0.85 CYP1A1 (0.36) KDM4EGAACYP1A1CYP2D6CYP2B6
SCHEMBL27599284 0.85 SERPINE1 (0.37) CYP1A1CYP2D6CYP2B6CYP2C19CYP3A43
SCHEMBL5236382 0.83 DPP4 (0.40) KDM4EALDH1A1GAAHPGDCYP1A1
SCHEMBL5236373 0.83 DPP4 (0.40) KDM4EALDH1A1GAAHPGDCYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1355886-B1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2007-07-11 EP disclosed
US-7034039-B2 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-25 US disclosed
US-20040082607-A1 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082607-A1 Fused heterocyclic compounds DPP7, DPP4, METAP1 KDM4E 897/4885ALDH1A1 387/4885GAA 310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.